<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00312351</url>
  </required_header>
  <id_info>
    <org_study_id>EOP1014</org_study_id>
    <nct_id>NCT00312351</nct_id>
  </id_info>
  <brief_title>A Clinical Trial to Explore the Safety and Efficacy of Three Different Doses of Pegaptanib Sodium in Patients With Wet Age-Related Macular Degeneration (AMD)</brief_title>
  <official_title>An Exploratory Randomized, Double-Masked, Multi-Center Comparative Trial, in Parallel Groups, to Explore the Safety and Efficacy of Three Different Doses of Intravitreous Injections of Pegaptanib Sodium (Anti-VEGF Pegylated Aptamer) Given Every 6 Weeks for 102 Weeks, in Patients With Subfoveal Neovascular Age-Related Macular Degeneration (AMD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eyetech Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Eyetech Pharmaceuticals</source>
  <brief_summary>
    <textblock>
      The purpose of this trial is to compare the ability of three different doses of pegaptanib
      sodium to safely and effectively minimize fluid leakage within the eye, thereby stabilizing
      or improving vision in patients with wet AMD. The study will also examine the effects of
      pegaptanib sodium on the cornea and sensory retina of patients with wet AMD.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>April 2006</start_date>
  <completion_date>November 2006</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <enrollment>262</enrollment>
  <condition>Macular Degeneration</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pegaptanib sodium</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects of either gender, aged 50 years or greater.

          -  Subfoveal choroidal neovascularization (CNV) due to AMD.

          -  Best corrected visual acuity in the study eye between 20/40 and 20/320.

          -  Normal electroretinogram, and corneal endothelial cell density of 1500 cells/mm2 or
             more.

        Exclusion Criteria:

          -  Any prior photodynamic therapy (PDT) with Visudyne or thermal laser to the study eye.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Charlotte Eye, Ear, Nose and Throat Associates, P.A.</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 6, 2006</study_first_submitted>
  <study_first_submitted_qc>April 7, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 10, 2006</study_first_posted>
  <last_update_submitted>January 12, 2007</last_update_submitted>
  <last_update_submitted_qc>January 12, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 15, 2007</last_update_posted>
  <keyword>AMD</keyword>
  <keyword>Age-Related Macular Degeneration</keyword>
  <keyword>Macular Degeneration</keyword>
  <keyword>Macugen</keyword>
  <keyword>pegaptanib sodium</keyword>
  <keyword>ERG</keyword>
  <keyword>specular microscopy</keyword>
  <keyword>Age-Related Mcular Degeneration (AMD)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

